论文部分内容阅读
阿霉素(Adriamycin)是广谱抗癌药物,特别是对多种晚期癌病的症状缓解,有显著效果。但也存在严重的剂量限制性心肌毒性,据欧美国家大规模临床统计,药物引起心脏毒性的死亡率是1.7～2.2%,如果一般累积剂量在500mg/M~2以下,很少出现充血性心力衰竭,发生率不到1.0%。因此开展临床血药浓度监测,取得病人个体化药代动力学参数,是提高治疗效果,保证安全的重要方法之一。
Adriamycin is a broad-spectrum anticancer drug with a significant effect, especially on the remission of symptoms of many advanced cancers. However, there is also a serious dose-limiting myocardial toxicity, according to large-scale clinical statistics in Europe and the United States, the mortality rate of drug-induced cardiotoxicity is 1.7 to 2.2%, if the general cumulative dose of 500mg / M ~ 2, rarely congestive heart failure Failure, the incidence of less than 1.0%. Therefore, to carry out clinical blood drug concentration monitoring and to obtain personalized pharmacokinetic parameters of the patient is one of the important ways to improve the treatment effect and ensure the safety.